Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Up 126.3% in July

Alzamend Neuro, Inc. (NASDAQ:ALZN) saw a significant increase in short interest in July. As of July 31st, there was short interest totalling 17,200 shares, an increase of 126.3% from the July 15th total of 7,600 shares. Based on an average daily trading volume, of 18,100 shares, the short-interest ratio is currently 1.0 days. Approximately 2.1% of the company’s shares are sold short.

Alzamend Neuro Price Performance

ALZN stock traded down $0.01 during trading on Wednesday, reaching $2.02. The company had a trading volume of 6,503 shares, compared to its average volume of 12,727. Alzamend Neuro has a 52 week low of $1.84 and a 52 week high of $51.24. The company has a market cap of $16.12 million, a P/E ratio of -2.01 and a beta of 0.03. The business has a 50 day moving average of $3.92 and a 200 day moving average of $6.74.

Hedge Funds Weigh In On Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Virtu Financial LLC bought a new stake in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned approximately 0.38% of Alzamend Neuro as of its most recent filing with the Securities and Exchange Commission (SEC). 49.61% of the stock is currently owned by institutional investors.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.